유방암에서 mTOR 및 pAkt의 발현과 에스트로겐/ 프로게스테론 수용체와의 연관성 및 예후에 관한 분석
The Relationship Between Estrogen/Progesterone Receptor and Expression of mTOR/pAkt Proteins and the Analysis of Prognosis in Breast Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway is a critical signaling pathway downstream of the growth factor receptor tyrosine kinase that regulates cell growth and survival. Rapamycin, an inhibitor of the mTOR, possesses antitumor activity against many tumors including breast cancer, especially against estrogen receptor (ER) positive breast cancer cell lines. In this study, the expression of mTOR and pAkt in breast cancer, its association with ER/progesterone receptor (PR) and prognosis were examined. Methods: Formalin fixed paraffin-embedded 170 cases of the breast cancer were immunohistochemically stained, using rabbit monoclonal antibody mTOR and rabbit monoclonal antibody pAkt. Based on this, the expression pattern of ER/PR and mTOR/pAkt were analyzed, and outcomes were also investigated. Results: mTOR expression was positive in 110 of 170 cases (64.7%) and pAkt expression was positive in 130 of 170 cases (76.5%). In correlation between clinicopathologic factors and mTOR/pAkt expression, mTOR expression was correlated with ER/PR positive and pAkt expression was correlated with age (>65), postmenopause. But there is no statistically significant in correlation between survival and mTOR/pAkt expression. Conclusion: The expression of pAkt was correlated with postmenopausal women and increased age, and we found the expression of ER/PR increased mTOR. The results provide a rationale basis for future clinical development of mTOR inhibitor combined ER inhibitor in breast cancer.
Abstract
Purpose: The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway is a critical signaling pathway downstream of the growth factor receptor tyrosine kinase that regulates cell growth and survival. Rapamycin, an inhibitor of the mTOR, possesses antitumor activity against many tumors including breast cancer, especially against estrogen receptor (ER) positive breast cancer cell lines. In this study, the expression of mTOR and pAkt in breast cancer, its association with ER/progesterone receptor (PR) and prognosis were examined. Methods: Formalin fixed paraffin-embedded 170 cases of the breast cancer were immunohistochemically stained, using rabbit monoclonal antibody mTOR and rabbit monoclonal antibody pAkt. Based on this, the expression pattern of ER/PR and mTOR/pAkt were analyzed, and outcomes were also investigated. Results: mTOR expression was positive in 110 of 170 cases (64.7%) and pAkt expression was positive in 130 of 170 cases (76.5%). In correlation between clinicopathologic factors and mTOR/pAkt expression, mTOR expression was correlated with ER/PR positive and pAkt expression was correlated with age (>65), postmenopause. But there is no statistically significant in correlation between survival and mTOR/pAkt expression. Conclusion: The expression of pAkt was correlated with postmenopausal women and increased age, and we found the expression of ER/PR increased mTOR. The results provide a rationale basis for future clinical development of mTOR inhibitor combined ER inhibitor in breast cancer.
참고문헌 (27)
- Mondesire WH, "Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells", Clin Cancer Res, 10, pp.7031~7042 (2004)
- Witton CJ, "Determining sensitivity to rapamycin and its analogues in breast cancer patients", Breast Cancer Res, 7, pp.41~42 (2005)
- Bachman KE, "The PIK3CA gene is mutated with high frequency in human breast cancers", Cancer Biol Ther, 3, pp.772~775 (2004)
- Slamon DJ, "Human breast cancer: correlation of relapse and survival with amplification of the HER-2", neu oncogene, 1987, pp.235, 177~182
- Akcakanat A, "The rapamycin-regulated gene expression signature determines prognosis for breast cancer", Mol Cancer, 8, pp.75~ (2009)
- Vézina C, "Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle", J Antibiot (Tokyo), 28, pp.721~726 (1975)
- Garber K, "Rapamycin’s resurrection: a new way to target the cancer cell cycle", J Natl Cancer Inst, 93, pp.1517~1519 (2001)
- Sehgal SN, "Rapamycin: a novel immunosuppressive macrolide", Med Res Rev, 14, pp.1~22 (1994)
- Douros J, "New antitumor substances of natural origin", Cancer Treat Rev, 8, pp.63~87 (1981)
- Meric F, "Translation initiation in cancer: a novel target for therapy", Mol Cancer Ther, 1, pp.971~979 (2002)
- Chan S, "Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer", Br J Cancer, 91, pp.1420~1424 (2004)
- Yu K, "mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer", Endocr Relat Cancer, 8, pp.249~258 (2001)
- Simoncini T, "Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase", Nature, 407, pp.538~541 (2000)
- Sun M, "Phosphatidylinositol-3-OH Kinase (PI3K)", AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K, 2001, pp.61, 5985~5991
- Chang SB, "Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells", J Surg Res, 138, pp.37~44 (2007)
- Chollet P, "Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer", Clin Breast Cancer, 7, pp.336~338 (2006)
- Sadler TM, "Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus", Endocr Relat Cancer, 13, pp.863~873 (2006)
- Baselga J, "Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer", J Clin Oncol, 27, pp.2630~2637 (2009)
- Anagnostou VK, "High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma", Clin Cancer Res, 15, pp.4157~4164 (2009)
- Zeng Q, "Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study", Eur J Cancer, 46, pp.1132~1143 (2010)
- Chacón RD, "Triple-negative breast cancer", Breast Cancer Res, 12(Suppl 2), pp.S3~ (2010)
- Yu P, "Clinical significance of pAKT and CD44v6 overexpression with breast cancer", J Cancer Res Clin Oncol, 136, pp.1283~1292 (2010)
- Zhou X, "Activation of the Akt", mammalian target of rapamycin, Clin Cancer Res, pp.2004, 10[DOI]
- Murakami D, "Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy", Gastric Cancer, 10, pp.45~51 (2007)
- 이경화, "Prognostic Value of Phosphorylated Akt and Survivin Expression in Gastric Adenocarcinoma", Journal of Pathology and Translational Medicine, 44(3), pp.252~258 (2010), 대한병리학회
- Pantuck AJ, "Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy", Cancer, 109, pp.2257~2267 (2007)
- Di Cosimo S, "Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy", Breast Cancer Res, 11(Suppl 3), pp.S25~ (2009)